NCT07477704
A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
Recruiting
PHASE2Ages 18–80InterventionalTreatmentRegeneron Pharmaceuticals
~420 participants
Updated 2026-07-22 on ClinicalTrials.gov
What's tested:Alirocumab
At a glance
Recruiting sites
34 of 34 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percent change in LDL-C
Measured over From Baseline through Week 12
Conditions
Where it's being run
34 sites across 19 statesTexas6
Florida4
California3
Alabama2
Georgia2
North Carolina2
Oklahoma2
South Carolina2
Study leadership
- Clinical Trial Management · STUDY_DIRECTOR · Regeneron Pharmaceuticals
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Percent change in LDL-CFrom Baseline through Week 12